Article
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
The Journal of clinical investigation - 1 Jun 2016
Mehnert Janice M, Panda Anshuman, Zhong Hua, Hirshfield Kim, Damare Sherri, Lane Katherine, Sokol Levi, Stein Mark N, Rodriguez-Rodriquez Lorna, Kaufman Howard L, Ali Siraj, Ross Jeffrey S, Pavlick Dean C, Bhanot Gyan, White Eileen P, DiPaola Robert S, Lovell Ann, Cheng Jonathan, Ganesan Shridar
Abstract excerpt
Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti-PD-1 therapy in some patients provides no benefit and/or results in adverse side effects. The factors that determine whether patients will be drug sensitive or resistant are not fully understood; therefore, genomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.